@Article{信息:doi 10.2196 / /移动医疗。5026，作者=“Morton, Katie和Sutton, Stephen和Hardeman, Wendy和Troughton, Jacqui和Yates, Tom和Griffin, Simon和Davies, Melanie和Khunti, Kamlesh和Eborall, Helen”，标题=“一个短信和计步器计划，以促进2型糖尿病高危人群的身体活动:props后续支持计划的发展”，期刊=“JMIR mHealth uHealth”，年=“2015”，月=“12月”，日=“15”，卷=“3”，数=“4”，页=“e105”，关键词=“身体活动;移动健康;短信;计步器;裁剪;2型糖尿病;背景:移动健康技术(mHealth)是降低2型糖尿病(T2DM)风险的一种有前途的策略。props试验调查了结构化的基于团体的教育是否单独或补充后续支持计划，结合自我监测与计步器和定制的短信在促进和维持2型糖尿病高危人群的身体活动方面是有效的。目的:本文描述了props后续支持计划的迭代开发，并为其可接受性和可行性提供证据。 Methods: We used a modified mHealth development framework with four phases: (1) conceptualization of the follow-on support program using theory and evidence, (2) formative research including focus groups (n=15, ages 39-79 years), (3) pre-testing focus groups using a think aloud protocol (n=20, ages 52-78 years), and (4) piloting (n=11). Analysis was informed by the constant comparative approach, with findings from each phase informing subsequent phases. Results: The first three phases informed the structure, nature, and content of the follow-on support program, including the frequency of text messages, the need for tailored content and two-way interaction, the importance of motivational messages based on encouragement and reinforcement of affective benefits (eg, enjoyment) with minimal messages about weight and T2DM risk, and the need for appropriate language. The refined program is personalized and tailored to the individual's perceived confidence, previous activity levels, and physical activity goals. The pilot phase indicated that the program appeared to fit well with everyday routines and was easy to use by older adults. Conclusions: We developed a feasible and innovative text messaging and pedometer program based on evidence and behavior change theory and grounded in the experiences, views, and needs of people at high diabetes risk. A large scale trial is testing the effectiveness of this 4-year program over and above structured group education alone. Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN): 83465245; http://www.controlled-trials.com/ISRCTN83465245/83465245 (Archived by WebCite at http://www.webcitation.org/6dfSmrVAe) ", issn="2291-5222", doi="10.2196/mhealth.5026", url="http://mhealth.www.mybigtv.com/2015/4/e105/", url="https://doi.org/10.2196/mhealth.5026", url="http://www.ncbi.nlm.nih.gov/pubmed/26678750" }